Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives $14.75 Consensus Target Price from Brokerages

Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) have been assigned an average recommendation of “Buy” from the six analysts that are presently covering the firm, MarketBeat.com reports. Six investment analysts have rated the stock with a buy recommendation. The average 1 year price target among brokers that have covered the stock in the last year is $17.33.

TNYA has been the topic of several recent analyst reports. HC Wainwright reiterated a “buy” rating and set a $18.00 target price on shares of Tenaya Therapeutics in a research note on Monday, November 25th. Canaccord Genuity Group reissued a “buy” rating and issued a $16.00 target price on shares of Tenaya Therapeutics in a research report on Friday, October 18th. Chardan Capital dropped their price target on shares of Tenaya Therapeutics from $20.00 to $18.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. Leerink Partners reissued an “outperform” rating on shares of Tenaya Therapeutics in a report on Friday, October 18th. Finally, Piper Sandler restated an “overweight” rating on shares of Tenaya Therapeutics in a report on Friday, October 18th.

Tenaya Therapeutics Trading Up 8.5 %

Shares of NASDAQ TNYA opened at $3.57 on Friday. The stock has a market cap of $282.82 million, a price-to-earnings ratio of -2.48 and a beta of 2.34. The stock’s 50-day moving average is $2.14 and its 200 day moving average is $2.84. Tenaya Therapeutics has a 1-year low of $1.61 and a 1-year high of $7.01.

Tenaya Therapeutics (NASDAQ:TNYA) last issued its earnings results on Wednesday, November 6th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.07. On average, analysts forecast that Tenaya Therapeutics will post -1.35 EPS for the current fiscal year.

Hedge Funds Weigh In On Tenaya Therapeutics

Institutional investors have recently made changes to their positions in the business. Synovus Financial Corp bought a new position in Tenaya Therapeutics in the third quarter worth approximately $28,000. SG Americas Securities LLC bought a new position in Tenaya Therapeutics in the 3rd quarter worth $49,000. The Manufacturers Life Insurance Company raised its holdings in Tenaya Therapeutics by 43.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 23,199 shares of the company’s stock worth $72,000 after purchasing an additional 7,000 shares during the period. Algert Global LLC bought a new stake in Tenaya Therapeutics during the second quarter valued at about $74,000. Finally, XTX Topco Ltd grew its holdings in Tenaya Therapeutics by 51.2% during the third quarter. XTX Topco Ltd now owns 49,290 shares of the company’s stock valued at $95,000 after purchasing an additional 16,687 shares during the period. Institutional investors own 90.54% of the company’s stock.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.